Skip to main content
. 2007 Nov;14(11):751–766. doi: 10.1111/j.1365-2893.2007.00865.x

Fig. 4.

Fig. 4

Long-duration treatment of (a) HBeAg-positive chronic hepatitis B (CHB); (b) HBeAg-negative CHB – proportion of cohort in compensated cirrhosis (CC), decompensated cirrhosis (DCC) or hepatocellular carcinoma (HCC) states during each cycle.